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INTRODUCTION 
 
Programmed cell death, or apoptosis, is essential for the proper 
development and maintenance of tissue homeostasis in metazoans. 
Cells that are damaged, dangerous or superfluous undergo apoptosis 
and are removed unobtrusively by professional phagocytes, such as 
macrophages and dendritic cells [1,2,3]. This is unlike other forms of 
cell death such as necrosis, which elicits an inflammatory response due 
to the release of noxious cellular contents from the dying cell. The 
apoptotic demise of the cell is executed by a group of proteases, 
known as caspases (cysteine-dependent asparate-specific proteases), 
which once activated, cleave vital cellular substrates. 
Upstream of caspase activation, a group of proteins that plays a 
vital role in the regulation of apoptosis signaling is the Bcl-2 family of 
proteins. These proteins are defined by the presence of at least one, 
and up to four, regions of sequence homology known as Bcl-2 
homology (BH) domains and the family comprises three sub-classes, 
each distinguished by their functional role (Figure 1A,B) [4]. The 
first of these sub-classes are the pro-survival Bcl-2 proteins (Bcl-2 
itself, Bcl-xL, Bcl-w, Mcl-1 and Bfl-1) which are responsible for the 
protection of cells against various death stimuli such as cytokine 
withdrawal or DNA damage. The second sub-class contain the 
Bax/Bak proteins. These are multi-BH domain-containing proteins 
that are closely related to their pro-survival counterparts in their 
domain architecture. However, in contrast, Bax and Bak promote cell 
death and are critical mediators of apoptosis as evidenced by the 
severe phenotype of the bax-/-bak-/- mice, and the resistance of cells 
derived from these mice to most forms of stress-induced apoptosis, 
and the enforced expression of the BH3-only proteins [5]. These 
BH3-only proteins constitute the third sub-class of Bcl-2 family 
proteins and are the initiators of the apoptotic cascade. As suggested 
by their name, BH3-only proteins are related to each other, and to 
other members of the Bcl-2 family, by the presence of just the BH3 
domain. The BH3-only proteins are upregulated transcriptionally and 
post-translationally upon receipt of a death stimulus. 
A number of models have been proposed for how BH3-only 
proteins activate Bax and Bak. In one model, known as “indirect 
activation”, Bax and Bak activation is spontaneous and their pro-
apoptotic activities are exerted once released from pro-survival protein 
sequestration. This release occurs following binding of the BH3-only 
 
 
 
 
 
 
 
 
 
proteins to the pro-survival proteins [6,7]. An alternate model, known 
as “direct activation”, suggests that a sub-group of the BH3-only 
proteins are able to bind directly to, and trigger the activation of Bax 
and Bak. Here, pro-survival proteins act to sequester these “activator” 
BH3-only proteins [8,9,10,11]. A third model, known as the 
“embedded together” model proposes that the pro-survival proteins 
are dominant-negative regulators of Bax and Bak and bind both the 
BH3-only proteins as well as Bax and Bak in the mitochondrial 
membrane, thereby inhibiting apoptosis [12,13]. Very recently, a 
fourth “unified” model encompassing the major aspects of the above-
mentioned models has been proposed [14]. Significantly, this model 
takes into account the differential efficiencies by which each model of 
cell death activation occurs. Regardless of the mechanism by which 
Bax/Bak activation occurs, the key point of no return in the apoptotic 
cascade is the permeabilization of the outer mitochondrial membrane 
(MOMP). MOMP occurs when Bax/Bak oligomerize on the outer 
mitochondrial membrane, forming pore-like structures through which 
apoptogenic factors such as cytochrome c are released into the cytosol 
from the space between the inner and outer mitochondrial 
membranes. Cytochrome c then binds to an adaptor protein known as 
Apaf-1, which leads to the formation of an oligomeric assembly 
known as the “apoptosome”. Formation of the apoptosome leads to 
the activation of the cellular demolitionists, the caspases and in turn 
this spells the inevitable death of the cell. It should be noted that 
alternative pathways independent of the Apaf-1-cytochrome c axis 
have been reported [15]. 
Given the importance of apoptosis in the maintenance of tissue 
homeostasis and the removal of rogue cells, it comes as no surprise 
that dysfunctional apoptosis signaling leads to disease manifestation. 
Deficient apoptosis leads to an accumulation of unwanted cells and 
the inability to respond normally to apoptotic stimuli. Diseases such 
as cancer and autoimmune disorders are characterized by this. In 
contrast, excessive apoptosis results in diseases in which cells are 
removed inappropriately. Examples of these include neurodegenerative 
disorders. The therapeutic targeting of the Bcl-2-regulated apoptotic 
pathway has therefore been an attractive avenue for the treatment of 
diseases characterized by such defects. As one would expect, a detailed 
molecular understanding of how these proteins interact functionally 
and structurally is essential to the development of safe and effective 
drugs.  
Since the initial discovery of the bcl-2 gene [16] and the 
subsequent characterization of the function of its gene product, Bcl-2 
[17], more than 20 years ago, our understanding of how these 
proteins work together to regulate apoptosis has expanded 
enormously. In addition, a large body of structural studies has been 
undertaken that have provided us with a “family album” of the 
various components that make up the Bcl-2-regulated apoptotic 
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pathway. Here, we will review the structural information available to 
us in this area, as well as discuss where structural information is still 
lacking. 
 
STRUCTURAL BIOLOGY OF THE BCL-2 PROTEINS 
 
The first atomic resolution structure of a Bcl-2 family member 
was that of the mammalian pro-survival protein Bcl-xL [18] (Figure 
1C). The structure revealed an eight helical bundle in which the α-
helices are connected by loops of varying lengths. Two central helices, 
α5 and α6, form the core of the protein and are primarily 
hydrophobic in nature. These are sandwiched on one side by the α1 
and α2 helices, and on the other side by α3 and α4. Two more 
helices, α7 and α8, complete the structure. The BH1, BH2 and BH3 
domains are not contiguous in the primary sequence, however, in the 
three-dimensional fold, these conserved domains form a surface 
exposed hydrophobic groove. This groove is formed from helices α2- 
α5 and α8 and is the binding site for BH3 domains from the pro-
apoptotic proteins (discussed below). 
Since then, structures of three more of the five mammalian pro-
survival proteins in their unliganded states have been determined (Bcl-
2, Bcl-w, and Mcl-1) and reveal that the structure of Bcl-xL, typifies a 
Bcl-2 protein fold [19,20,21,22]. It should be noted that all 
structures of pro-survival proteins have been solved utilizing C-
terminally-truncated recombinant proteins. Structures of truncated 
pro-survival Bcl-2 proteins from the nematode C. elegans (CED-9) 
[23], and the schistosome S. japonicum (sjA)  [24], have also been 
solved, and demonstrate the conservation of the fold through 
evolution. The closest to a full-length structure is that of Bcl-w [25]. 
Here, an additional helix, α9, binds into its own hydrophobic groove 
and gets displaced upon ligand binding [26]. Close inspection and 
comparison of the four structures reveals differences in the nature of 
the different hydrophobic grooves. These include, the “openness” of 
the groove and their electrostatic character (Figure 1D,E). These 
idiosyncrasies could potentially contribute to the selectivity 
differences observed in pro-survival protein:pro-apoptotic protein 
interactions. 
 
The Bax/Bak proteins are multi-domain pro-apoptotic proteins 
defined by the presence of all four of the conserved BH domains 
(Figurre 1B) [4]. The structures of both Bax and Bak are very similar 
to that of their pro-survival relatives. Both adopt a helical bundle 
defined by the same α-helical arrangement. The structure of Bax, 
determined by NMR, most resembles that of Bcl-w, whereby its α9 
helix binds into its own hydrophobic groove, burying hydrophobic 
residues that would have otherwise been exposed (Figure 1F) [27]. 
This feature is thought to contribute to the cytosolic localization of 
this protein, which following a death stimulus translocates to the 
mitochondria by a mechanism that is still not well understood. In the 
case of Bak, the key difference between its structure and that of its 
pro-survival relatives, is its significantly constricted hydrophobic 
groove, which may contribute to the inhibition of ligand binding 
[28,29]. One crystal structure of Bak also showed that it forms a zinc-
dependent homodimer [28], where zinc plays an inhibitory role on its 
pro-apoptotic function. However, in a more recent study by Dewson 
et al., mutation of the proposed zinc-binding site had little effect on 
its activity [30].  
 
As their name suggests, the BH3-only proteins only possess 
homology with other Bcl-2 proteins in their BH3-domain. Most of 
these proteins (such as Bim, Bad and Bmf) are largely intrinsically 
unstructured proteins in the absence of their binding partners [25]. 
The only three-dimensional structure of a BH3-only protein solved to 
date is that of Bid (Figure 1G) [31,32]. This structure closely 
resembles the fold of a multi-domain Bcl-2 protein (Figure 1C) but 
with some key differences, such as a much shallower hydrophobic 
groove that is typical of a pro-survival Bcl-2 protein. By using 
spectroscopic and sequence analyses, it has been predicted that in 
addition to Bid, the only other BH3-only protein that possibly 
possesses a defined structure is Bik [25], though this structure has yet 
to be solved.  
 
All current models of apoptotic regulation highlight the 
importance of interactions between pro-survival Bcl-2 proteins and 
pro-apoptotic BH3-only proteins. These interactions are mediated by 
the BH3 domain on the pro-apoptotic molecule. We now have 
numerous structures of these complexes with all pro-survival proteins, 
except Bcl-w, and of a variety of BH3 domains from BH3-only 
proteins including Bim, Puma, Bad, Noxa, Bid and Bmf (typically 
using synthetic BH3 domain peptides of ~16-26 residues in length) 
[33,34,35,36,37] (Figure 1H). These complexes all demonstrate a 
similar mode of interaction: each of the four conserved hydrophobic 
residues on the helical BH3 domain project into hydrophobic pockets 
along the length of the conserved binding groove on the pro-survival 
protein. The conserved aspartic acid residue in the BH3 domain also 
forms a salt bridge with the conserved arginine residue in the BH1 
domain found on all mammalian pro-survival proteins (i.e in the 
NWGR motif), and biochemical studies have shown this interaction 
is important for BH3 domain binding and biological activity. 
Additional interactions (hydrogen bonds, salt bridges) are also formed 
by some of the non-conserved residues along the BH3 domain with 
residues lining the groove. 
Complexes of the same pro-survival protein bound to multiple 
BH3 ligands have demonstrated a degree of plasticity in the binding 
groove of some pro-survival proteins [35,36,37,38,39,40]. In Bcl-xL, 
for example, this usually involves helices α3 and α4, with α3 in 
particular seen to range from being highly helical in some structures to 
essentially unstructured, depending on the ligand 
[35,36,38,39,40,41,42]. (Figure 1I). Similar plasticity has also been 
noted for A1 (the mouse orthologue of Bfl-1) [37]. These differences 
in the binding groove results in alterations in the network of 
interactions that occur, particularly between the non-conserved 
residues in the BH3 domains and the residues lining the grooves. This 
is believed to be a determinant of the selectivity patterns apparent in 
BH3 domain:pro-survival protein interactions [37].  
A different type of structural plasticity was observed in CED-9 
when it binds to a peptide corresponding to the BH3 domain of the 
C. elegans BH3-only protein, Egl-1. Although Egl-1 BH3 engages the 
CED-9 ligand-binding groove similarly to the way mammalian BH3 
sequences engage their pro-survival binding partners, a large 
movement of the unstructured loop region between helices α4 and α5 
was noted when the liganded and apo structures are compared [43] 
(Figure 1J). This conformational change is required for downstream 
activation of the pathway, as discussed below. 
Several groups, including us, have explored the idea of using 
BH3 peptides incorporating non-natural amino acids as a means of 
stabilizing them against proteolysis for therapeutic applications 
[39,44,45,46,47,48,49]. Structures we have solved of  BH3  peptides  
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Figure 1. A) Schematic of the Bcl-2 regulated cell death in humans. B) Domain architecture of the Bcl-2 family of proteins. These proteins are characterized by the 
presence of up to 4 regions of sequence homology, known as Bcl-2 homology (BH) domains. C) The structure of the pro-survival protein, Bcl-xL (PDB: 1MAZ) 
comprises a helical bundle arrangement that typifies the Bcl-2 protein family fold. Surface electrostatic representation of D) Bcl-xL and E) Bfl-1 bound to Bim BH3 
peptide show different charge distributions in the BH3 domain binding groove (PDB: 3FDL and 2VM6 respectively). F) Structure of the multi-domain pro-
apoptotic protein, Bax (PDB: 1F16). The structure resembles that of the pro-survival protein and has the C-terminal α9 helix binding in the canonical hydrophobic 
groove. G) The only BH3-only protein, Bid, has a three-dimensional structure (PDB: 2BID) similar to that of the pro-survival and multi-domain pro-apoptotic 
proteins. Only Bid and possibly Bik are structured BH3-only proteins, the remaining members of this sub-class are thought to be intrinsically unstructured 
proteins. H) The structure of the BH3 domain from Bim (pink) bound to Bcl-xL (green) (PDB: 3FDL) is typical of interactions between BH3 domains from pro-
apoptotic proteins and pro-survival proteins. I) Overlay of structures of Bcl-xL from complexes of it in its apo form (yellow, PDB: 1PQ0), or bound to ABT-737 
(green, PDB: 2XYJ), an ABT-737 analogue (blue, PDB: 3INQ) or Bim BH3 peptide (pink, PDB: 3FDL) highlights significant differences in the arrangement of helices 
α3 and α4 that line the ligand binding groove. J) CED-9 also undergoes significant conformational changes upon binding the BH3 domain from Egl-1. The 
unstructured loop connecting helices α4-α5 (boxed) moves significantly in the complexed structure (pink, peptide has been removed for clarity, PDB: 1TY4), 
compared to in apo-CED-9 (blue, PDB: 1OHU). 
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incorporating β-amino acids show similar binding modes to those of 
natural BH3 domains consisting of α-amino acids, even when the β-
amino acids have non-native cyclic side chains [39,44,45]. Strategies 
to lock BH3 domains into a helical conformation using hydrocarbon 
staples have also been successful. A structure of one of these bound to 
Mcl-1 also suggests an essentially canonical binding mode [49], 
although additional interactions involving the staple itself were 
observed, and perhaps contribute to the high affinity of that ligand. 
 
In addition to binding BH3-only proteins, pro-survival proteins 
also inhibit apoptosis by engaging Bax and Bak in their “activated” 
conformation. As with binding to BH3-only proteins, these 
interactions also involve the BH3 domains from the pro-apoptotic 
Bax/Bak molecules. At present our structural knowledge of these 
interactions is still limited to peptides of the Bax and Bak BH3 
domains bound to various mammalian pro-survival proteins including 
Bcl-xL [40,50], Bcl-2 [51] Mcl-1 [50], as well as to a pro-survival 
protein from schistosomes [24]. These structures all show that they 
engage the same hydrophobic cleft that the BH3 domains from BH3-
only proteins bind into, and that their mode of binding is very similar. 
Although these structures are limited to just the BH3 domains, they 
do provide some insights into the nature of the conformational 
changes that must occur when Bak and Bax adopts its active form. For 
example, the structures of full-length Bax and Bak show that the 
conserved hydrophobic residues on their BH3 domains, essential for 
binding pro-survival proteins, pack into the core of the protein 
[18,27,29]. Hence for these to be able to bind a pro-survival protein 
(or indeed another Bax/Bak molecule to form a homo-oligomer), the 
BH3 domain must become everted from the rest of the structure. 
Furthermore, our recent structures of the Bax BH3 domains bound to 
Bcl-xL and Mcl-1 also indicate that this conformational change 
involves the α2 and α3 helices, which normally subtend an angle of 
nearly 90 degrees to one other in the apo form, but essentially 
becomes a contiguous helix upon pro-survival protein binding [50]. 
Hence, although these structures only represent a fragment of the 
entire Bax/Bak molecule, the information they contain extends 
somewhat beyond the binding interface. 
 
The binding of BH3-only proteins to their pro-survival protein 
counterparts is one mechanism by which Bax/Bak activation can 
occur. The alternate way is through the direct binding of “activator” 
BH3-only proteins to Bax and Bak. Whilst many structures of BH3-
only proteins in complex with pro-survival proteins have been 
determined, the structures of BH3-only proteins in direct complex 
with either Bax or Bak have proven elusive up until recent years. 
Utilizing NMR spectroscopy together with biochemical analyses, a 
model by which Bax activation through direct binding of BH3-only 
proteins, namely Bim, has been proposed [52,53]. A novel binding 
site formed by α1 and α6 residues on Bax, distinct from the canonical 
hydrophobic groove engaged by BH3-only proteins on pro-survival 
proteins, was identified. This site is also defined by a surface 
hydrophobic groove, which is notably shallower than the canonical 
site on the opposite face of the molecule. Binding of Bim to this site 
triggers a series of structural changes that involves the displacement of 
the α1/α2 loop into an “open” conformation exposing a well-
characterized N-terminal epitope. The putative transmembrane α9-
helix is then mobilized to allow for membrane insertion and the Bax 
BH3 domain in turn is exposed. The exposed Bax BH3 domain 
propagates the activation of other inactive Bax molecules in the same 
way that Bim activates Bax. These studies importantly suggest a novel 
regulatory binding site on Bax that had not previously been 
considered. It will be interesting to determine if the same binding site 
also exists on Bak. 
 
One of the most important outcomes of the structures of BH3 
domain:pro-survival protein complexes has been the development of 
small-molecule drugs that can induce apoptosis in a manner similar to 
that of the BH3-only proteins (i.e. by engaging the ligand-binding 
groove on the pro-survival protein). The best studied of such so-
called “BH3-mimetics” is ABT-737 which binds Bcl-xL, Bcl-2 and 
Bcl-w with high affinity and was discovered through screening of 
small molecule fragment libraries that bind Bcl-xL using NMR (“SAR 
by NMR”) [54,55]. Insights into how such fragments could be 
assembled to form a high-affinity ligand were provided by the 
structures of the peptidic BH3 domain:pro-survival protein 
complexes. High-resolution structures of ABT-737 (and derivatives) 
bound to Bcl-xL show exactly how it engages the ligand-binding 
groove, and how it might be altered to change its binding profile 
[38,56]. An orally available form of ABT-737, ABT-263, is now in 
clinical trials for treatment of various cancers including leukaemia, 
lymphoma and small-cell lung cancer [57], and a more selective 
compound, ABT-199, which targets only Bcl-2 with high affinity has 
also recently entered clinical trials. Numerous other BH3-mimetics 
have been described [58], though many of these have been shown to 
kill cells via mechanisms that do not require Bax and Bak [59] 
suggesting they are not bona-fide BH3-mimetics. For most of these 
there is also no structural data to support their mode-of-action. 
 
There still remain some significant gaps in the structural biology 
of the Bcl-2 family of proteins. As highlighted above, we do not yet 
have any structures of full-length BH3-only proteins bound to pro-
survival proteins, though these are not likely to be very revealing 
beyond the BH3 peptide-bound  structures currently available, as 
most BH3-only proteins (with the exception of Bid and Bik) are likely 
to be intrinsically unstructured. More interesting, however, will be 
structures of full-length Bax or Bak bound to pro-survival proteins. 
These are likely to be informative as they should reveal both the 
“activated” conformations of Bax and Bak, and also whether there are 
binding interfaces in addition to the BH3 domain, as suggested by 
recent studies [14]. Similarly, there are no structures of a Bax/Bak 
oligomer of any type. Some recent structures of Bcl-xL and Bcl-w 
dimers have provided some clues as to how these oligomers might 
form [60,61], though none reveal a BH3-in-groove dimer suggested 
by the recent convincing biochemical data for how Bax/Bak dimerizes 
[62,63]. A higher-order oligomer of Bax/Bak would also be extremely 
interesting, as this would reveal how the damage to the mitochondrial 
outer membrane occurs. This is the critical, point-of-no-return step in 
the apoptotic cascade, and it is still unclear whether well-defined 
pores are formed by the Bax/Bak oligomers, or whether they create 
less well-defined aggregates that simply lead to MOM damage 
resulting in leakage of the contents of the mitochondrial 
intermembrane space into the cytosol. In addition, a structure of a 
BH3 “activator” sequence bound to Bax/Bak would be useful for a 
complete understanding of how Bax/Bak activation occurs. Due to 
the unstable nature of the BH3 “activator”:Bax complex, only a model 
of the complex was inferred from key distance information obtained 
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from NMR spectroscopy, though this was validated through 
biochemical and cell-based assays. Finally, we still don’t fully 
understand why, given the similarities between the three-dimensional 
structures of the pro-survival proteins and Bax/Bak, does one confer a 
cell’s survival whereas the other promotes its demise? 
 
STRUCTURAL BIOLOGY OF THE APOPTOSOME 
 
Apoptosis has been well characterized in a number of model 
organisms and there are significant differences in the architecture of 
the cell death pathways between them. Nevertheless, they are all 
similar in that they culminate in the activation of the caspases.  These 
proteases are typically present in cells in an inactive zymogen form, 
allowing for the rapid onset of cell death when required [64,65,66]. 
In vertebrates and insects two levels of activation occurs – first an 
“initiator” caspase (Caspase-9 in humans, DRONC in insects) is 
activated, and this can then cleave and activate downstream “effector” 
caspases (Caspase-3/7 in humans, DRICE in flies). In C. elegans the 
system is simpler due to the presence of just a single executioner 
caspase, CED-3. The active form of caspases is an obligate dimer, 
though the zymogen (procaspase) form of initiators is monomeric 
[64,65,66]. Activation and maturation of executioner caspases 
involves their proteolysis into a large (~20 kDa) α and small (~10 
kDa) β subunits which form a (α/β)2 holoenzyme. The large subunit 
contains the catalytic dyad whilst residues important for substrate 
binding are contributed by the small subunit. Numerous structures of 
caspases have been solved in different forms including zymogen, 
active, as well as bound to chemical and protein inhibitors (e.g. p35 
and IAP domains), and have been extensively reviewed elsewhere [64]. 
In short, the catalytic domain, derived from a single procaspase has 
the same fold in all caspases and is composed of α twisted β-sheet 
sandwiched between two layers of α-helices.  
Whilst effector caspases are dimeric and are activated following 
cleavage by initiator capases, the initiators are monomeric, and require 
an activation “platform” that allows for their dimerization and auto-
activation. Two models have been proposed for initiator caspase 
activation. A proximity induced dimerization model whereby the 
platform serves to increase the local concentration above the 
dissociation constant for dimer formation [67,68]. By contrast, the 
induced conformation model argues that a conformational change, 
induced by the caspase binding to the platform, is most important for 
activation [69,70,71].  
Perhaps the most exciting development in our understanding of 
caspase activation has come from the determination of structures of 
these activation platforms, “apoptosomes”, that facilitate this 
initiation of the caspase cascade. Apoptosome assemblies are found in 
a range of organisms and involve related oligomeric molecules: Apaf-1 
in humans [72], CED-4 in C.elegans [73] and DARK in insects [74], 
which all appear to assemble differently for caspase activation. These 
proteins all have a similar domain architecture involving an N-
terminal caspase recruitment domain (CARD) that can form 
homotypic interactions with CARD domains that are also found on 
the initiator caspases. This N-terminal protein interaction domain 
distinguishes initiator from effector caspases, which do not possess 
one. The CARD is followed by a nucleotide-binding α/β fold, a 
small helical domain (HD1), a winged helix domain (WHD) and 
then a second helical domain (HD2). Apaf-1 and DARK also have C-
terminal regions that include WD40 domains. These molecules are 
known (together with the “R proteins” found in plants) as NB-
ARC’s (nucleotide binding, Apaf-1, R proteins and CED-4) and 
belong to the AAA+ superfamily of ATPases. In the last five years, 
significant progress has been made into determining the structures of 
these death assemblies, providing critical insights into the mechanism 
by which apoptosis is executed in different organisms. Below we 
review key features of each of these structures, and highlight what we 
still do not yet fully understand about their mechanisms of action. 
 
Unlike in the nematode (see below), activation of caspases in 
mammals requires cytochrome c, which is released from the 
mitochondria following Bax/Bak oligomerization. Cytochrome c is 
required for activation of Apaf-1 [72], which exists in the cytosol in 
an inactive or so-called “closed” conformation. It has been known for 
some time that switching to the “open” conformation following 
cytochrome c binding also involves exchange of a nucleoside 
diphosphate (ADP/dADP) for a nucleoside triphosphate 
(ATP/dATP) [75], though the exact roles of both cytochrome c and 
nucleotide in Apaf-1 activation have been obscure. Apaf-1 (like CED-
4) contains a AAA+ ATPase domain (with Walker A and Walker B 
boxes for binding ATP and Mg2+), and has been reported to possess 
low level ATPase activity, though non-hydrolysable analogues of ATP 
can induce apoptosome formation [76], hence it was uncertain 
whether chemical energy from nucleotide hydrolysis was required for 
the assembly process.  
In 2005, a crystal structure of Apaf-1 bound to ADP was 
determined, though this lacked the C-terminal WD40 domains 
[77,78]. Nevertheless, the location of the ADP molecule and the 
network of bridging interactions it forms suggested it could serve to 
lock the structure in an inactive conformation. Very recently, however, 
a crystal structure of full-length murine Apaf-1 was determined 
(Figure 2A) though, in this structure, electron density for the CARD 
domain was not visible (probably due to the high ionic strength of the 
crystallization buffer which disrupts charged interactions holding it in 
place and rendering it highly flexible) [79]. Nevertheless, a possible 
mechanism by which Apaf-1 is held in the closed conformation was 
apparent, and by comparison with a the cryo-electron microscopy 
(EM) model of the holo-apoptosome (Figure 2B) which represents 
the “open” conformation [80,81], it was possible to assess the 
structural changes that probably occur following binding of 
cytochrome c.  
In the structure, the WD40 repeats form tandem seven and eight 
blade β-propellers (as also predicted from a previous cryo-EM study) 
[80,81] and these sit on top of the nucleotide binding and 
oligomerization domain. In their model, the authors propose that 
binding of cytochrome c between the β-propellers, causes one 
propeller (WD1) to swing out from its resting position, releasing the 
attachment of the nucleotide binding domain (NBD) and helical 
domain 1 (HD1) to the WD40 repeat regulatory domain. This 
movement of NBD1 and HD1 exposes the contact area for 
oligomerization and also relocates the CARD, allowing the 
apoptosome to assemble as a heptameric wheel with the CARDs 
arranged in a central hub. The mechanism they propose requires no 
chemical energy from nucleotide hydrolysis during the opening 
process, though exchange of ADP for ATP (which occurs in 
monomeric Apaf-1) is probably required as the-phosphate on the 
ATP is proposed to form a salt-bridge with Arg265, and this is 
important for the movement of the NDB-HD1 sub-domains.  
As described above, cryo-EM studies provided important 
complementary data to the higher resolution crystallographic analysis 
of Apaf-1, and enabled insight into how it adopts its activated, 
oligomeric conformation. Associated biochemical analyses have also 
been very informative for providing a model of how caspase-9 and the 
Apaf-1 heptameric platform interact and function to activate caspase-
3 [81]. This model shows that the CARD’s of Apaf-1 and caspase-9  
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associate in a disk-like structure that sits above the platform. These 
CARDs are tethered by flexible linkers joining them to the rest of the 
protein, and these linkers are of a critical length for optimal 
activation. The CARD-disk appears to be located off-centre relative 
to the central hub of the platform. It is suggested that this asymmetry 
limits the number of procaspase-9 catalytic domain binding sites on 
the central hub, and consequently, that the holo-apotosome may only 
contain a single active procaspase-9, consistent with earlier 
biochemical studies that had also shown a stoichimetry of just 1 or 2 
caspase-9 molecules per apoptosome, rather than 1 procaspase-9 per 
Apaf-1 molecule [82]. The binding of a single procaspase-9 molecule 
argues against the proximity-induced model of caspase-9 activation, 
and is consistent with the induced conformation model. Elegant 
biochemical studies from the Bratton group provide important 
additional insights into the dynamic nature of procaspase-9 
interactions with the apoptosome and argue for a proteolytic-based 
molecular timer paradigm of caspase activation which is dictated, in 
part, by the differential affinities they report of procaspase-9 and the 
cleaved enzyme for Apaf-1 [82,83]. In the structure, it also seems that 
procaspase-9 and caspase-3 have overlapping binding sites, and due to 
the asymmetry in the disk, multiple caspase-3 dimers could bind 
together with a singly bound procaspase-9 catalytic domain. 
As described above, we now have available a combination of 
high-resolution structures for Apaf-1 (closed form) and low-
resolution structures of the assembled apoptosome. Obviously, further 
higher resolution structures would aid in resolving the precise 
mechanism by which caspase activation occurs in mammals. For 
example, the open form of Apaf-1 could be useful for deciphering the 
role of nucleotide hydrolysis in apoptosome formation. Moreover, any 
structures of apoptosome complexes with caspases bound could 
resolve exactly how the zymogen forms are processed, though 
technical issues associated with producing all intermediate complexes, 
combined with the apparently dynamic and complex nature of 
activation steps, may restrict whether the entire process can be 
captured at high resolution. 
 
The cell death pathway that is perhaps best understood is that in 
C.elegans as we now have crystal structures of each event leading to 
the activation of the caspase CED-3. This pathway (Figure 2C) is 
fundamentally different to the intrinsic apoptosis pathway in humans 
as there is no Bax/Bak-like molecule required for the release of 
cytochrome c to switch the activation platform from its autoinhibited 
Figure 2. A) Crystal structure of Apaf-1 (PDB: 3SFZ). The domains are colored as follows: NBD (pink), HD1 (blue), WHD (yellow), HD2 (green), WD1 (seven blade 
propellor, orange), WD2 (eight blade propellor, teal). B) Cryo-EM structure of the DARK apoptosome (PDB: 3IZ8) shows an octameric platform (color coding as in 
part A); C) Schematic of the apoptotic cell death pathway in C.elegans. D) Crystal structure (PDB: 2A5Y) of CED-9 (green) bound to a CED-4 dimer (subunits in blue 
and pink, E) Top and F) side views of the crystal structure of the octameric CED-4 apoptosome (PDB: 3LQQ; CARD: grey, α/β-fold: pink, HD1: blue, WHD: yellow, 
HD2: green). 
 
 
Structural biology of intrinsic apoptosis 
6 
Volume No: 1, Issue: 1, April 2012, e201204007 Computational and Structural Biotechnology Journal | www.csbj.org 
to activated state (as occurs with Apaf-1). Instead, the worm Bcl-2-
like protein CED-9 inhibits cell death by directly engaging CED-4 
(the Apaf-1 orthologue) at the mitochondria. In response to some 
death stimulus, the BH3-only protein Egl-1 is transcriptionally 
upregulated and binds to CED-9. This allows for the release of CED-
4 into the cytosol where it can engage CED-3, leading to its activation 
and the eventual demise of the cell. Structural studies have now 
elucidated the mechanisms involved in the release of CED-4 by Egl-1 
and the assembly of the apoptosome that allows for CED-3 
activation.  
A significant breakthrough in our understanding of how cell 
death is activated in nematode worms was achieved when the CED-
4:CED-9 complex structure was determined [84,85] (Figure 2D). 
Unexpectedly, this structure, together with associated biochemical 
studies, showed CED-4 forms an asymmetric dimer that is engaged 
with a single CED-9 molecule. This interaction involves a different 
interface on CED-9 from that involved in BH3 ligand binding. As 
described above, comparison of the apo-CED-9 structure with the 
BH3-bound CED-9 structure showed that, upon ligand binding, a 
significant conformational change occurs in the unstructured loop 
between helices α4-α5 which is close to the interface with one of the 
CED-4 molecules (Figure 1J). As such, movement of this loop 
disrupts the interaction with CED-4, and releases it into the cytosol 
where it can then oligomerize. 
The second key study which revealed the structural basis of the 
C.elegans apoptsosome assembly was published in 2010 and provided 
further surprises regarding the mechanism of caspase activation. This 
structure showed that the assembled apoptosome is an octamer 
consisting of a tetramer of the asymmetric dimer that is bound by 
CED-9 [86] (Figure 2E,F). As such, no major conformational change 
is associated with the CED-4 apoptosome assembly (unlike the Apaf-
1 apoptsosome). The surprise here was that the octamer forms a 
funnel like structure with the CARDs located toward the narrow end 
and the other domains extending essentially linearly towards the wider 
end (Figure 2F). A principle determinant of this apoptosome 
assembly is the interactions involving the α/β domain, both within a 
CED-4 molecule and between adjacent CED-4 dimers. Further 
biochemical and structural studies using cryo-electron microscopy 
revealed that, unexpectedly, each apoptosome only binds to two 
CED-3 molecules within the space, or “hutch”, inside the funnel. 
This localization of just two CED-3 molecules within this hutch 
apparently facilitates their dimerization, enhancing its proteolytic 
activity. 
 
Whilst combined these studies provide unparalleled insight into 
apoptosome formation and caspase activation, there remain some 
unanswered questions. These primarily relate to how the CED-3 
zymogen binds to, and is activated by, the apoptosome. The studies 
reported used purified recombinant CED-3 without its CARD 
domain due to solubility issues associated with producing the 
unprocessed form. Consequently, the role for the CED-3 CARD and 
the nature of the events involving the unprocessed form of CED-3 
engaging the CED-4 CARD domains (which are located on top of 
the funnel), then adopting the active dimer conformation within the 
hatch are still to be determined.  
 
The Drosophila apoptososme consists of the Apaf-1 orthologue 
DARK which assembles into a platform necessary for the activation 
of the initiator caspase DRONC, and downstream activation of the 
executioner procaspase, DRICE. As in mammals, DARK possesses a 
regulatory domain consisting of WD40 repeats, though mounting 
evidence suggests that cytochrome c is not required for DARK 
assembly or DRONC activation.  
All of our knowledge of the Drosophila apoptosome structure 
has been obtained from cryo-EM studies [87,88,89]. An earlier study 
had suggested that the Drosophila apoptosome could be a double-
ringed structure [88], though a more recent study showed this was 
probably a concentration-dependent phenomenon, and that a single-
ringed structure (as seen in the human apoptosome) is the more likely 
physiologically relevant form [89].  
In several studies, including the most recent report of a 6.9Å 
structure, the DARK single (and double) ring(s) are shown to consist 
of eight subunits (compared to seven in the Apaf-1 assembly) with 
the hub of the wheel-like complex comprising the NBD’s [89] Unlike 
in Apaf-1 and CED-4, the CARDs are positioned on top of the 
central hub creating a crown-like arrangement. Interestingly, there is a 
clear path for dATP exchange in the Drosophila apoptosome, due to 
a much shorter HD1-WHD linker compared to that in Apaf-1. In 
vitro, dATP exchange appears to provide the driving force for DARK 
platform assembly as cytochrome c is not required, and although an 
alternative activating ligand cannot be entirely ruled out, assembly of a 
DARK-DRONC apoptosome capable of cleaving DRICE (without 
cytochrome c) suggests that such a ligand is probably not required. 
 
Our knowledge of the fly apoptosome comes entirely through 
relatively low-resolution cryo-EM studies. Hence, higher resolution 
crystal structures are required. Structures of the assembled 
apoptosome that include DRONC will also be important, as 
modelling based on the current best structure suggests that the 
DRONC CARD can engage the DARK CARD’s, but at higher 
radius a clash likely occurs with the seven-blade propellor, suggesting 
some structural re-arrangements occur during caspase activation. The 
nature of such structural changes is lacking and will be required for a 
complete understanding of caspase activation in the fly. 
 
SUMMARY AND OUTLOOK 
 
Structural studies have been central to our understanding of how 
apoptosis is regulated. Indeed, these structures have sometimes 
revealed surprises that would not have been apparent if we relied only 
on biochemical and biological studies for informing how the process 
is controlled. It is particularly interesting that whilst all of the 
apoptotic cell death pathways studied to date possess similar 
components with very similar three-dimensional structures, these all 
engage each other in different ways, resulting in vastly different 
mechanisms for the activation of the caspases, the ultimate event in all 
apoptosis pathways. As indicated above, some significant gaps in the 
structural biology of this process still exist, though the available 
structures have enabled drugs such as ABT-263 to be developed. 
Hopefully, future advances that close the remaining gaps will not only 
provide us with a more complete picture of apoptotic regulation (and 
evolution) at high-resolution, but perhaps provide further clues as to 
how new drugs could be developed to intervene in cells where 
apoptosis is dysregulated. 
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